Birgit Klein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Birgit Klein has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Bleilevens
Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, 52074 Aachen, Germany
1 shared publication - Elmar Stickeler
Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, 52074 Aachen, Germany
1 shared publication - Jochen Maurer
Department of Gynecology and Obstetrics, Universitätsklinikum Aachen, Aachen, Germany; Department of Gynecology and Obstetrics, RWTH Aachen University, Aachen, Germany, Germany
1 shared publication - Julia Wittenborn
Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, 52074 Aachen, Germany
1 shared publication - Laila Najjari
Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, 52074 Aachen, Germany
1 shared publication - Thomas Hansen
Department of Obstetrics and Gynecology, University Hospital Aachen (UKA), 52074 Aachen, Germany
1 shared publication
Latest Publications
- Open Access
- 11 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2508
Comparison of Serum and Urine as Sources of miRNA Markers for the Detection of Ovarian Cancer
Ovarian cancer is the second most fatal gynecological cancer. Early detection, which could be achieved through widespread screening, has not yet had an impact on mortality. The aim of our pilot study was to investigate the expression of miRNAs analyzed by a human miRNA microarray chip in urine and serum of patients with ovarian cancer. We analyzed three serum and three urine samples from healthy donors and five serum and five urine samples from patients with ovarian cancer taken at first diagnosis, before any treatment. We selected the seven miRNAs with the highest expression fold change in the microarray chip (cancer vs. control) in urine and serum, for validation by qPCR. We were able to validate two of the seven miRNAs in serum. In contrast to these findings, we were able to validate all of the top seven miRNAs identified in urine using qPCR. The top seven miRNAs in urine identified by microarray chip showed significantly greater differences in expression between patients with ovarian cancer and healthy donors compared to serum. Based on our finding, we can suggest that urine as a biomaterial is more suitable than serum for miRNA profiling by microarray chip in the search for new biomarkers in ovarian cancer.
- 11 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2508
Open AccessComparison of Serum and Urine as Sources of miRNA Markers for the Detection of Ovarian Cancer
Ovarian cancer is the second most fatal gynecological cancer. Early detection, which could be achieved through widespread screening, has not yet had an impact on mortality. The aim of our pilot study was to investigate the expression of miRNAs analyzed by a human miRNA microarray chip in urine and serum of patients with ovarian cancer. We analyzed three serum and three urine samples from healthy donors and five serum and five urine samples from patients with ovarian cancer taken at first diagnosis, before any treatment. We selected the seven miRNAs with the highest expression fold change in the microarray chip (cancer vs. control) in urine and serum, for validation by qPCR. We were able to validate two of the seven miRNAs in serum. In contrast to these findings, we were able to validate all of the top seven miRNAs identified in urine using qPCR. The top seven miRNAs in urine identified by microarray chip showed significantly greater differences in expression between patients with ovarian cancer and healthy donors compared to serum. Based on our finding, we can suggest that urine as a biomaterial is more suitable than serum for miRNA profiling by microarray chip in the search for new biomarkers in ovarian cancer.